K ATP channels (ATP-sensitive potassium channels), comprising four subunits each of Kir6.2 (inwardly rectifying potassium channel 6.2) and the SUR1 (sulfonylurea receptor 1), play a central role in glucosestimulated insulin secretion by the pancreatic β-cell. Changes in the number of channels at the cell surface are associated with genetic diseases of aberrant insulin secretion, including CHI (congenital hyperinsulinism) and NDM (neonatal diabetes mellitus). The present review summarizes advances in our understanding of the vesicular trafficking of normal K ATP channels and how genetic mutations in Kir6.2 interfere with such trafficking. A mutation, E282K, causing CHI, was found to disrupt a DXE [di-acidic ER (endoplasmic reticulum)-exit signal], thereby preventing its assembly into COPII (coatamer protein II)-coated vesicles and subsequent ER exit. The resultant decrease in the cell-surface density of the channel could explain the disease phenotype. Two mutations, Y330C and F333I, reported in patients with NDM, disrupted an endocytic traffic signal, thereby impairing CCV (clathrin-coated vesicle) formation and endocytosis. The consequent increase in the density of K ATP channels, together with an attenuated sensitivity to ATP reported previously, may account for the severe form of NDM.
Introduction
K ATP channels (ATP-sensitive potassium channels) play a crucial role in glucose-stimulated insulin secretion by coupling the metabolic status ([ATP]/[ADP] ratio) of the pancreatic β-cell with electrical activity of the plasma membrane [1] [2] [3] [4] . This ability is conferred by the unique property of K ATP channels: they are inhibited by ATP and activated by Mg-ADP. A rise in blood glucose concentration increases glucose uptake and metabolism by the pancreatic β-cell, resulting in an increase in the intracellular [ATP]/[ADP] ratio. This leads to the closure of K ATP channels, producing a membrane depolarization that activates voltage-gated calcium channels. Entry of Ca 2+ through the activated calcium channels leads to a rise in intracellular Ca 2+ concentration, which stimulates insulin secretion. The resultant increase in plasma insulin levels restores blood glucose concentration to normal. During starvation, when blood glucose levels are low, metabolism of glucose in the β-cell is reduced and the intracellular [ATP]/[ADP] ratio falls. This leads to the opening of K ATP channels, producing a membrane hyperpolarization that keeps voltage-gated calcium channels closed, thereby reducing the intracellular Ca 2+ concentration and insulin secretion. Thus K ATP channels play a key role in adjusting the amount of insulin secreted in accordance with changes in blood glucose levels.
Underpinning this role is a series of reports that inherited mutations associated with the genes encoding the channel lead to diseases of aberrant insulin secretion in humans [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Mutations that reduce the functional activity of the channel at the cell surface of the β-cell lead to CHI (congenital hyperinsulinism), a genetic disorder characterized by unregulated insulin secretion and severe hypoglycaemia [5, 6] . On the other hand, mutations that enhance the activity of the channel cause NDM (neonatal diabetes mellitus), where insulin secretion is seriously compromised, with resting blood glucose levels approaching extreme values [1, 7, 8, 10] . Investigations into how these mutations result in the disease phenotype led to the discovery of two distinct types of mechanisms, one in which the functional properties of the channel are affected [1, [5] [6] [7] 11] and the other where trafficking of the channel to, and out of, the plasma membrane is compromised [12] [13] [14] . The present review summarizes advances in our current understanding of the trafficking of K ATP channels, with an emphasis on the mechanisms by which inherited mutations affect vesicular trafficking.
K ATP channel structure, function and pharmacology
The pancreatic K ATP channel is a large octameric complex comprising four subunits each of Kir6.2 (inwardly rectifying potassium channel 6.2) and the SUR1 (sulfonylurea receptor 1) [1] [2] [3] [4] 15, 16] . Kir6.2 is encoded by KCNJ11 and SUR1 by ABCC8. Kir6.2 is a member of the Kir channels. It comprises two membrane-spanning helices (M1 and M2) either side of an extracellularly facing re-entrant P-loop containing the K + channel signature sequence responsible for ion selectivity. SUR1 is a member of the ABC (ATP-bindingcassette) protein family, to which CFTR (cystic fibrosis transmembrane conductance regulator) belongs [17] . It has a regulatory role, providing most of the channel-sensitivity to nucleotides via its cytosolic nucleotide-binding domains [1] [2] [3] [4] . SUR1 also contains distinct binding sites for the potassium channel opener drug, diazoxide, and the inhibitory sulfonylurea drugs, tolbutamide and glibenclamide [1] [2] [3] [4] 18] . Both types of drug are currently in clinical use: diazoxide is used to suppress insulin secretion in patients with CHI, whereas the sulfonylurea drugs are used to stimulate insulin secretion in patients with T2DM (Type 2 diabetes mellitus).
The three-dimensional structure of the channel has recently been determined by cryoelectron microscopy [19] . The structure is consistent with the previous evidence that the central core of the octamer comprises four subunits of Kir6.2, with the SUR1 subunits located at the periphery of the complex [15, 16] . The resolution of the complex (18 Å ; 1 Å = 0.1 nm), however, is not high enough to discern the details, including the molecular interface between Kir6.2 and SUR1. An atomic structure of the Kir6.2 tetramer, however, could be modelled based on the crystal structures of the bacterial Kir channel homologue, Kirbac1.1, and the intracellular domains of Kir3.1 [20] . At the cytoplasmic end of the tetramer lies a binding site for the inhibitory ATP [21] . Figure 1 shows the structure of Kir6.2, including the location of trafficking motifs discussed in the present review.
Biosynthesis, forward trafficking and CHI
Expression of KCNJ11 and ABCC8 genes is controlled by a common regulatory promoter. Zerangue et al. [22] showed that both Kir6.2 and SUR1 possess the 'RKR' (single-letter amino acid code; R, arginine; K, lysine) ER (endoplasmic reticulum) localization motifs in the cytoplasmic domains and that these motifs prevent independent trafficking of the subunits to the cell surface. Complete assembly of the subunits into an octameric complex appears to be mandatory for trafficking to the cell surface. Any unassembled subunits that escape the ER have their RKR motifs exposed, leading to their recognition by the COPI (coatamer protein I) coatamers and subsequent retrieval to the ER via COPIcoated vesicles [23] . It is unclear whether, in addition to the retrieval function, the RKR motif also functions as an ER retention signal. The mechanism by which the channel assembly inactivates the RKR signals is not fully understood. It has been proposed that in the fully assembled state, the RKR motifs are sterically masked by the partner subunits. Recent studies implied an important role for 14-3-3 proteins in controlling forward trafficking of the channel [23] . It was suggested that 14-3-3 proteins mask the RKR signals in the fully assembled channel, thereby preventing their interaction with COPI and promoting surface expression [23] .
Unfolded and improperly folded proteins remain in the ER. Several genetic mutations associated with CHI, detected largely in SUR1, prevent cell-surface expression. With the exception of one mutation (R1394H/SUR1), which causes retention of the channel in the TGN (trans-Golgi network) [13] , all these mutations result in ER retention, presumably due to misfolding [12, 14] . Trafficking of mutant channels retained in the TGN could be fully rescued with the channel agonist, diazoxide [13] . In contrast, trafficking of mutant channels The assembly of the vesicle begins with the Sec12-facilitated exchange of GTP for GDP on Sar1 and recruitment of Sar1-GTP to the ER membrane (step 1). This is followed by the sequential recruitment of the heterodimeric Sec23/24 (step 2), cargo, K ATP channel (step 3) and finally the Sec13/31 coat proteins (step 4) at the ER-exit sites. This assembly leads to the formation of a prebudding complex, which when fully formed is released into the cytoplasm as a COPII-coated vesicle for transport to the Golgi apparatus.
(B) Schematic diagram depicting CCV-mediated endocytosis. Briefly, the µ2 subunit of the AP2 complex binds to the endocytic motif located in the cytoplasmic domains of Kir6.2 (step 1), following which clathrin coat proteins are added (step 2) and budding of CCV takes place. When fully formed, the vesicle is released into the cytoplasm by the action of the dynamin GTPase.
(some, but not all) retained in the ER could be rescued partially with the channel antagonist, glibenclamide [14] .
In the present review, we report our studies with a recently reported novel Kir6.2 mutation, E282K, found in a patient diagnosed with CHI [24] . When tested in heterologous expression systems, the E282K mutation prevented expression of functional K ATP channels at the cell surface due to retention in the ER. A simple explanation for this effect would be that the mutation inhibits the ability of Kir6.2 to assemble with SUR1; the inhibition could result from either gross misfolding or loss of ionic interaction between Glu 282 of Kir6.2 and a positively charged residue on SUR1. The latter seems plausible because the predicted location of Glu 282 is on the surface of the cytoplasmic domain of Kir6.2 [20] , where it is more likely to participate in a salt bridge with SUR1 than in folding. Co-immunoprecipitation studies, however, demonstrated that the mutation had no effect on the ability of Kir6.2 to interact with SUR1. Co-expression studies revealed that the mutant subunit was able to form functional channels with wild-type Kir6.2, excluding the effect, if any, of the mutation on folding of Kir6.2. Thus the mechanism by which the E282K mutation causes ER retention of the channel is likely to be mechanistically different from other mutations reported so far. An examination of the amino acid sequence revealed that the Glu 282 residue is preceded by an acidic residue at position -2, making the D 280 LE 282 sequence a potential ER-exit signal [25] [26] [27] [28] .
ER-exit signals play an important role in the transport of proteins from the ER to the Golgi apparatus by means of transport vesicles [25] [26] [27] [28] . Several types of ER-exit signals have been identified that include di-acidic motifs [(D/E)X(D/E), where X represents any amino acid], dihydrophobic motifs (FF, YY, LL or FY), YXXXNPF and LXXLE motifs. The mechanism by which these signals promote the exit of proteins from the ER has been studied extensively (for reviews, see [25, 26, 28] ). In brief, proteins (cargo) bearing these signals exit the ER at specialized regions termed the ER-exit sites (referred to as ERES), where they are packaged into COPII-coated vesicles (Figure 2) . Assembly of cargo into these vesicles involves a group of proteins, collectively known as the COPII coat. COPIIcoated vesicle formation is initiated by the activation of Sar1-GTPase through Sec12 (a guanine-nucleotide-exchange factor)-induced exchange of GDP for GTP. Activated Sar1-GTP partitions into the ER membrane and recruits the Sec23-Sec24 complex. Sec24 then binds the cargo via the cytoplasmically exposed ER-exit signal on the cargo, producing prebudding complexes. Sec13-Sec31 complexes then bind to these prebudding complexes, generating COPII-coated vesicles (Figure 2A) . Although recruitment of cargo into COPII vesicles could occur by non-specific mechanisms (bulk-flow), this is thought to be very inefficient, and recruitment of most proteins, including ERGIC-53 (ER-Golgi intermediate compartment-53) and Kir2.1, relies on the recognition of discrete ER-exit signals by Sec24 [25, 26, 28] . Genetic mutations associated with Sar1 and Sec proteins have been shown to be associated with human diseases [29, 30] .
We have obtained several lines of evidence to support the idea that the D 280 LE 282 sequence in Kir6.2 functions as a bona fide ER-exit signal: first, we found that mutation of either of the two conserved charged residues Asp 280 and Glu 282 , but not the unconserved Leu 281 , prevented the ER exit. Secondly, dominant-negative constructs of Sar1, Sar1-T39N (Sar1-GDP) and Sar1-H79G (Sar1-GTP) prevented the ER exit and surface expression of wild-type K ATP channels in both HEK-293 cells (human embryonic kidney cells) and the rat pancreatic β-cell line, INS1e. Thirdly, incubation at a low temperature (10
• C) resulted in the accumulation of wild-type, but not the mutant (E282K) K ATP channels, at the ER-exit sites.
Sharma et al. [31] reported that a dileucine (LL) motif in the C-terminus of SUR1 serves as a forward traffic signal, but the mechanism by which this signal increases the surface expression remains to be determined. Although this motif could potentially bind COPII, SUR1 was unable to support the ER exit of K ATP channels lacking a functional DXE (di-acidic ER-exit signal) motif. The location of the ER exit and endocytic signals on Kir6.2 ( Figure 1 and see below) is somewhat surprising given that current models propose that SUR1 surrounds the Kir6.2 tetramer.
Endocytosis and neonatal diabetes
Following delivery to the plasma membrane, K ATP channels are internalized rapidly by CME (clathrin-mediated endocytosis) [32] . The process involves binding of the AP2 (adaptor protein 2) complexes to specific endocytic motifs on the channel, followed by the recruitment of clathrin coats, CCV (clathrin-coated vesicle) formation and subsequent release into the cytoplasm by the action of dynamin GTPases ( Figure 2B ). Two endocytic motifs have been reported in the C-terminus of Kir6.2: a dileucine motif [33] and a tyrosine-based motif (YXX , where Y is a tyrosine residue, X is any amino acid and is a hydrophobic residue) [34] . Although both signals could contribute to endocytosis of K ATP channels, studies by Mankouri et al. [34] suggest that the tyrosine-based motif plays a dominant role. While mutation of both motifs by alanine substitution caused an increase in the cell-surface density to almost similar levels compared with the wild-type channel, alanine mutation of the tyrosine-based motif Y 330 SKF 333 , but not the dileucine motif (L 355 L 356 ), fully blocked internalization [34] . The inability of this leucine pair to promote endocytosis was attributed to the fact that this sequence is preceded by an aspartate residue (D) at position -3, which makes the dileucine pair part of an acidic dileucine motif (DXXLL). The dileucine pair in this amino acid sequence context is incapable of recognizing the AP2 complexes and thus cannot promote endocytosis [32, 35] . The function of acidic dileucine motifs has been examined for a number of other membrane proteins where they play a role in regulating endocytic recycling [35] . Mutation of this motif increases cell-surface expression of some proteins including the mannose-6-phosphate receptor [35] . Thus the observed increase in cell-surface density of LL/AA mutant K ATP channels could be due to increased recycling.
Sagen et al. [36] reported two genetic mutations, Y330C and F333I, in Kir6.2 in patients with a severe form of NDM, with fasting blood glucose levels approaching as high as 70 mM (compared with 5 mM when normal). These mutations are located within the endocytic motif of Kir6.2. Like alanine mutations, they prevented endocytosis of K ATP channels, thereby increasing their cell-surface density ∼ 2-fold [34] . In addition to these effects on endocytic trafficking, these mutations also affected the functional properties of the channel: F333I caused impaired ATP binding/transduction, whereas Y330C impaired both ATP binding/transduction, as well as causing an increase in the intrinsic open probability of the channel [37] . These functional effects were attributed to the ability of these mutations to affect the inhibitory ATPbinding site on Kir6.2 to which Tyr 330 and Phe 333 residues are predicted to contribute [37] . Mankouri et al. [34] suggested that the Y330C and F333I mutations produce a severe form of the disease because they increase the channel activity due to their cumulative effect on both function and trafficking.
Conclusion
The findings reported in the present review illustrate the enormous potential that studies of genetic mutations have in revealing aspects of cell biology that are directly relevant to the physiology and pathophysiology of insulin secretion in humans. Some mutations could lead to the discovery of new roles for residues, whereas others could reveal the (patho)-physiological relevance of a functionally important residue/motif previously recognized. We have presented examples illustrating each of these potentials. The CHIcausing E282K mutation led to the discovery that Kir6.2 contains an ER-exit signal, and mutations that disrupt this signal prevent its recognition by the COPII coat machinery, thereby impairing the ER exit and surface expression of K ATP channels. In a second example, we demonstrated that a tyrosine-based endocytic signal present in Kir6.2 mediates endocytosis of K ATP channels and that NDM-causing genetic mutations impair the function of this signal, increasing the channel density at the cell surface; increase in channel density could contribute to the NDM phenotype. A key advantage of studies on genetic mutations is that any motifs, or paradigms, that they reveal have direct relevance to human disease and therefore could be exploited to develop new therapeutic strategies. For example, an agent that inhibits insertion of Kir6.2 into COPII-coated vesicles or enhances its incorporation into CCV could be used to stimulate insulin secretion in patients with T2DM. Recent genome-wide association studies have confirmed a significant link between single nucleotide polymorphism in KCNJ11 and Type 2 diabetes [38] , making Kir6.2 an attractive drug target.
